FDA Warns Novo Nordisk Over Unreported Ozempic Side Effects

Danish pharmaceutical giant Novo Nordisk has been hit with a severe warning letter from the U.S. Food and Drug Administration (FDA) for failing to promptly investigate and disclose adverse events linked to its blockbuster weight-loss and diabetes drugs. Most alarmingly, among the unreported Ozempic side effects cited by the agency are two deaths and one completed suicide.

The warning, dated March 5, stems from an FDA inspection of the company’s Plainsboro, New Jersey, headquarters early last year. According to the inspection report, Novo Nordisk neglected to file mandatory individual case safety reports for serious side effects, with some submissions delayed by more than 800 days. Regulators issued a harsh rebuke of the company, stating that Novo's written procedures actively inhibited proper surveillance. Furthermore, the FDA noted that these failures raise "serious concerns" regarding the company's ability to monitor the safety of its entire product portfolio.

In a public statement, Anna Windle, Novo Nordisk's head of clinical development, medical, and regulatory affairs, emphasized that the company takes the reporting requirements seriously and plans to resolve the FDA's concerns "expeditiously and holistically". However, the market has reacted poorly; Novo Nordisk’s stock has plummeted 27% year-to-date, pressured by this ongoing regulatory scrutiny and increased competition from Eli Lilly.

This latest reprimand is part of a broader streak of negative publicity for the drugmaker. In recent months, the FDA has criticized the company for misleading advertisements that framed Ozempic as superior while downplaying risks. Additionally, the company is dealing with significant Good Manufacturing Practice violations at a newly acquired facility in Bloomington, Indiana—issues that have already been explicitly tied to several FDA drug application rejections.

The company is also facing headwinds from Washington. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly targeted Novo Nordisk, criticizing Ozempic's pricing and previously rejecting a proposal to expand Medicare coverage for GLP-1 obesity drugs to millions of Americans.

---

🔖 Sources

FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths

Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals

Novo Nordisk's US headquarters under fire in latest FDA warning letter

---

Keywords: Unreported Ozempic Side Effects

Unreported Ozempic Side Effects

---